Skip to main content

NEW YORK (

TheStreet

) --

Pfizer

's

(PFE) - Get Pfizer Inc. Report

anti-smoking drug Chantix may increase the risk of heart attacks for patients with cardiovascular disease, the Food and Drug Administration

said

Scroll to Continue

TheStreet Recommends

on Thursday.

The agency cited a study of 700 people with heart disease where half of the patients took Chantix that found 2% of the Chantix users suffered non-fatal heart attacks vs. 0.9% for the placebo group. As a result of the findings, the FDA said additional safety information will be added to the Warnings and Precautions section of the drug's label.

But the FDA said in a statement: "The known benefits of Chantix should be weighed against its potential risks when deciding to use the drug in smokers with cardiovascular disease."

Pfizer's shares were at $20.12. down 0.4% during midday trading on Thursday. Year-to-date, the stock, a Dow component, is up 15%. Wall Street is bullish on the stock with 18 of the 22 analysts covering the shares at either strong buy (8) or buy (10). Revenue from Chantix totaled $199 million in the company's fiscal first quarter ended in March.

--

Written by Joe Deaux in New York.

>To submit a news tip, send an email to:

tips@thestreet.com